Skip to main content

Table 3 Serum PSA on each days after switching to lueprolide

From: Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonist

  Day 0 Day 1 Day 2 Day 5 Day 7
total (n = 39) 2.61 ± 3.86 2.47 ± 3.66 2.43 ± 3.75 1.95 ± 2.43 1.92 ± 2.63
3 m group (n = 10) 0.628 ± 0.611 0.614 ± 0.592 0.631 ± 0.625 0.665 ± 0.621 0.655 ± 0.614
2 m group (n = 10) 2.05 ± 4.30 1.94 ± 4.04 2.05 ± 4.31 2.01 ± 3.99 2.13 ± 4.44
1 m group (n = 19) 3.88 ± 4.21 3.66 ± 4.02 3.52 ± 4.10 2.58 ± 1.71 2.53 ± 1.68
  1. Data are presented as means ± SD (ng/ml) unless indicated otherwise
  2. PSA Prostate Specific Antigen